pharma · Alopecia areata · Multiple myeloma
First Biotech (Australia)
Pfizer Australia Pty Ltd
First Biotech (Australia) clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
- Founded
- 2017
- Employees
- 2
- Programs
- 126
- Drugs
- 208
- Patents
- 0
First Biotech (Australia) projects
7 ClinicalTrials.gov programs sponsored by First Biotech (Australia).
First Biotech (Australia) has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A8081075
Pfizer Australia Pty Ltd
This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
1 trial -
B7471015
Pfizer Australia Pty Ltd
VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA
1 trial -
C4221026
Pfizer Australia Pty Ltd
Solid tumors
1 trial -
C4951004/BHV3000-406
Pfizer Australia Pty Ltd
Migraine attacks with or without aura
1 trial -
C4951012/BHV3000-407
Pfizer Australia Pty Ltd
migraine headaches with or without aura
1 trial -
DAN-RSV
Pfizer Australia Pty Ltd
RSV-infection
1 trial -
LORLATINIB
Pfizer Australia Pty Ltd
Lung cancer
1 trial
Frequently asked questions
How many clinical projects does First Biotech (Australia) have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.